Michael Kotsanis

Mr Kotsanis is a seasoned executive with over 30 years of experience in the pharmaceutical industry and has significant senior leadership experience across the global pharmaceutical markets. He was formerly the Chief Commercial Officer and a Board Member of Synthon Holding BV, a Dutch based pharmaceutical company with global revenue over EUR250 million. Prior to Synthon, he served as President, Europe, Middle East and Africa, for Hospira and where he was responsible for delivering over US$500 million in annual revenue. Hospira was the global leader in generic injectable pharmaceuticals prior to its acquisition by Pfizer. Mr Kotsanis joined Hospira following its acquisition of Mayne Pharma in 2007, where he had served as President, Asia Pacific. He joined Mayne following their acquisition of FH Faulding in 2001, where he held responsibility for commercial activities of the pharmaceutical business in Australia and New Zealand. Prior to Faulding, Mr Kotsanis held a variety of sales and marketing positions with a German multinational pharmaceutical company over an 11 year period.

Company and Roles

Company
Title
Tenure
Since
ACR
Acrux Limited
  • Chief Executive Officer
  • Managing Director
9yrs, 3mthNov 2014

Holding

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ACR
Acrux Limited
30/06/231,511,083N/AN/AN/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
ACR
Acrux Limited
26/11/21
Issued
6,000,000$0.070$420,000Issue of securities
ACR
Acrux Limited
26/11/21
Cancelled
3,000,000$0.110$330,000Cancellation of securities
ACR
Acrux Limited
04/02/21
Issued
320,000$0.157$50,240Placement
ACR
Acrux Limited
03/02/21
Buy
191,083$0.157$30,000Participation in share purchase plan
ACR
Acrux Limited
16/03/20
Exercise
1,000,000$0.120$120,000Conversion of securities